Antiemetic efficacy of high-dose dexamethasone versus placebo in patients receiving cisplatin-based chemotherapy

A randomized double-blind controlled clinical trial

J. T. D'Olimpio, Fernando J. Camacho, P. Chandra, M. Lesser, M. Maldonado, D. Wollner, P. H. Wiernik

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

The antiemetic effect of short courses of high-dose dexamethasone was compared with that of placebo in 64 patients receiving cisplatin-based cancer chemotherapy, in a double-blind randomized clinical trial. All patients were receiving cisplatin for the first time. Dexamethasone was given intravenously (IV) at a dose of 20 mg, two hours before and 3, 6, 9, and 12 hours after chemotherapy. Patients were crossed over to dexamethasone on the second cycle of chemotherapy if they experienced unacceptable gastrointestinal (GI) toxicity after initial treatment with placebo. Nine of 32 patients receiving dexamethasone and seven of 32 patients receiving placebo did not vomit. The median duration of nausea was significantly shorter (one-half hour) for the dexamethasone-treated group compared with that of placebo (3 1/2 hours). The number of patients who experienced unacceptable GI toxicity was significantly greater (53%) for the placebo patients than for those treated with dexamethasone (25%). Patients crossing over to dexamethasone after initially receiving placebo had a median duration of nausea of 1 1/2 hours and 24% did not vomit, results comparable to the first treatment group. We conclude that high-dose dexamethasone is only minimally effective as an antiemetic agent in patients receiving cisplatin-based chemotherapy.

Original languageEnglish (US)
Pages (from-to)1133-1135
Number of pages3
JournalJournal of Clinical Oncology
Volume3
Issue number8
DOIs
StatePublished - Jan 1 1985

Fingerprint

Antiemetics
Controlled Clinical Trials
Dexamethasone
Cisplatin
Placebos
Drug Therapy
Nausea
Randomized Controlled Trials

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Antiemetic efficacy of high-dose dexamethasone versus placebo in patients receiving cisplatin-based chemotherapy : A randomized double-blind controlled clinical trial. / D'Olimpio, J. T.; Camacho, Fernando J.; Chandra, P.; Lesser, M.; Maldonado, M.; Wollner, D.; Wiernik, P. H.

In: Journal of Clinical Oncology, Vol. 3, No. 8, 01.01.1985, p. 1133-1135.

Research output: Contribution to journalArticle

@article{2b14231a582c4c6497744e4f4e09e42d,
title = "Antiemetic efficacy of high-dose dexamethasone versus placebo in patients receiving cisplatin-based chemotherapy: A randomized double-blind controlled clinical trial",
abstract = "The antiemetic effect of short courses of high-dose dexamethasone was compared with that of placebo in 64 patients receiving cisplatin-based cancer chemotherapy, in a double-blind randomized clinical trial. All patients were receiving cisplatin for the first time. Dexamethasone was given intravenously (IV) at a dose of 20 mg, two hours before and 3, 6, 9, and 12 hours after chemotherapy. Patients were crossed over to dexamethasone on the second cycle of chemotherapy if they experienced unacceptable gastrointestinal (GI) toxicity after initial treatment with placebo. Nine of 32 patients receiving dexamethasone and seven of 32 patients receiving placebo did not vomit. The median duration of nausea was significantly shorter (one-half hour) for the dexamethasone-treated group compared with that of placebo (3 1/2 hours). The number of patients who experienced unacceptable GI toxicity was significantly greater (53{\%}) for the placebo patients than for those treated with dexamethasone (25{\%}). Patients crossing over to dexamethasone after initially receiving placebo had a median duration of nausea of 1 1/2 hours and 24{\%} did not vomit, results comparable to the first treatment group. We conclude that high-dose dexamethasone is only minimally effective as an antiemetic agent in patients receiving cisplatin-based chemotherapy.",
author = "D'Olimpio, {J. T.} and Camacho, {Fernando J.} and P. Chandra and M. Lesser and M. Maldonado and D. Wollner and Wiernik, {P. H.}",
year = "1985",
month = "1",
day = "1",
doi = "10.1200/JCO.1985.3.8.1133",
language = "English (US)",
volume = "3",
pages = "1133--1135",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

TY - JOUR

T1 - Antiemetic efficacy of high-dose dexamethasone versus placebo in patients receiving cisplatin-based chemotherapy

T2 - A randomized double-blind controlled clinical trial

AU - D'Olimpio, J. T.

AU - Camacho, Fernando J.

AU - Chandra, P.

AU - Lesser, M.

AU - Maldonado, M.

AU - Wollner, D.

AU - Wiernik, P. H.

PY - 1985/1/1

Y1 - 1985/1/1

N2 - The antiemetic effect of short courses of high-dose dexamethasone was compared with that of placebo in 64 patients receiving cisplatin-based cancer chemotherapy, in a double-blind randomized clinical trial. All patients were receiving cisplatin for the first time. Dexamethasone was given intravenously (IV) at a dose of 20 mg, two hours before and 3, 6, 9, and 12 hours after chemotherapy. Patients were crossed over to dexamethasone on the second cycle of chemotherapy if they experienced unacceptable gastrointestinal (GI) toxicity after initial treatment with placebo. Nine of 32 patients receiving dexamethasone and seven of 32 patients receiving placebo did not vomit. The median duration of nausea was significantly shorter (one-half hour) for the dexamethasone-treated group compared with that of placebo (3 1/2 hours). The number of patients who experienced unacceptable GI toxicity was significantly greater (53%) for the placebo patients than for those treated with dexamethasone (25%). Patients crossing over to dexamethasone after initially receiving placebo had a median duration of nausea of 1 1/2 hours and 24% did not vomit, results comparable to the first treatment group. We conclude that high-dose dexamethasone is only minimally effective as an antiemetic agent in patients receiving cisplatin-based chemotherapy.

AB - The antiemetic effect of short courses of high-dose dexamethasone was compared with that of placebo in 64 patients receiving cisplatin-based cancer chemotherapy, in a double-blind randomized clinical trial. All patients were receiving cisplatin for the first time. Dexamethasone was given intravenously (IV) at a dose of 20 mg, two hours before and 3, 6, 9, and 12 hours after chemotherapy. Patients were crossed over to dexamethasone on the second cycle of chemotherapy if they experienced unacceptable gastrointestinal (GI) toxicity after initial treatment with placebo. Nine of 32 patients receiving dexamethasone and seven of 32 patients receiving placebo did not vomit. The median duration of nausea was significantly shorter (one-half hour) for the dexamethasone-treated group compared with that of placebo (3 1/2 hours). The number of patients who experienced unacceptable GI toxicity was significantly greater (53%) for the placebo patients than for those treated with dexamethasone (25%). Patients crossing over to dexamethasone after initially receiving placebo had a median duration of nausea of 1 1/2 hours and 24% did not vomit, results comparable to the first treatment group. We conclude that high-dose dexamethasone is only minimally effective as an antiemetic agent in patients receiving cisplatin-based chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0021806336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021806336&partnerID=8YFLogxK

U2 - 10.1200/JCO.1985.3.8.1133

DO - 10.1200/JCO.1985.3.8.1133

M3 - Article

VL - 3

SP - 1133

EP - 1135

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -